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Background: Cardiac ryanodine receptor (RYR2) and Kir2.1 (KCNJ2) mutations are a cause of catecholaminergic polymorphic ventricular 
tachycardia (CPVT), a lethal cardiac channelopathy. Here, we describe mutations in RYR2 and KCNJ2 in patients referred for FAMILION CPVT genetic 
testing.
Methods: Sequence analysis of 38 RYR2 exons was performed for 578 unrelated patients; analysis of an additional 28 RYR2 exons and KCNJ2 
was performed for the last 256 patients. All variants detected were interpreted with respect to more than 400 ostensibly healthy, ethnically-diverse 
control individuals and review of published literature.
Results: Possible CPVT-causing mutations in RYR2 and KCNJ2, absent from more than 800 reference alleles, were detected in 134 of the 578 
suspected CPVT patients. The mutation yield of the 38 exons analyzed by the first generation FAMILION CPVT genetic test was 22% among 578 
patients, while the yield of an additional 28 exons analyzed was 5% among the latter 256 patients. One hundred thirty patients had 116 distinct 
RYR2 mutations (106 missense, 6 splice variants, 1 frameshift and 3 non-frameshift mutations) located in 37 exons, 4 of which accounted for more 
than half of the RYR2 mutation yield. Five patients harbored 2 RYR2 mutations, and 1 patient harbored 3 RYR2 mutations. Three distinct missense 
mutations were detected in KCNJ2 in 4 patients, one of whom also had an RYR2 mutation.
Conclusions: Our study represents one of the largest cohorts systematically examined for mutations in RYR2 and KCNJ2, providing further 
insight into the spectrum and frequency of mutations in CPVT. Consistent with prior reports, most RYR2 mutations localized to just a few exons, 
which suggests these regions may represent areas of high specificity for pathogenicity. Compared to the expected RYR2 mutation yield of 55-65% 
for patients with a robust CPVT phenotype, the mutation yield in this cohort suggests the FAMILION CPVT genetic test is ordered clinically for a 
significant percentage of patients lacking diagnostic stigmata for this disease.
